Valby, Denmark, 25 October 2013 - H. Lundbeck A/S (Lundbeck) today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion and recommended marketing authorisation of Brintellix (vortioxetine) for the treatment of adults with Major Depressive Episodes, commonly referred to as depression.
Help employers find you! Check out all the jobs and post your resume.
